James Chih-Hsin Yang
Graduate Institute of Oncology, National Taiwan University Superintendent, National Taiwan University Cancer Center
ISY-1 "KRAS : a promising target in NSCLC"
LS14 "Treatment strategy for EGFR+ NSCLC"
Institut Gustave Roussy, Department of medical oncology, Thoracic Group, Villejuif, France
ISY-4 "BRAF, RET, MET, NTRK or HER2 altered NSCLC"
LS1 "EGFRm+ NSCLC: recent updates and optimal treatment strategy"
Pasi A. Janne
Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute
ISY-5 "Treatment of targeted therapy induced drug persistent disease"
Department of Pathology, University of Pittsburgh Medical Center
S10-1 "Preoperative Chemotherapy Evaluation"
Ming S. Tsao
Department of Pathology, Princess Margaret Cancer Centre and University of Toronto
S11-1 "Overview of 2020 WHO Classification for thoracic tumours"
Harry J. de Koning
Department of Public Health, Erasmus MC University Medical Centre
WS02-4 "NELSON Study"
Department of Thoracic Surgery, Royal Brompton Hospital
WS10-6 "Well differentiated adenocarcinoma, when to excise? The ground glass opacity less than 3cm"
Chinese University of Hong Kong
WS13-4 "Intratumoral heterogeneity in driven lung adenocarcinoma"
Department of Oncology, Karmanos Cancer Institute Wayne State University
WS16-5 "To treat, or not to treat"
Head of the Simple Structure of Thoracic-Pulmonary Medical Oncology at the Fondazione IRCCS, National Institute of Cancer Milan, Italy
LS18 "IMFINZI in ES-SCLC"